CN107073073B - 经肺施用绿脓菌素用于治疗细菌性呼吸道感染 - Google Patents

经肺施用绿脓菌素用于治疗细菌性呼吸道感染 Download PDF

Info

Publication number
CN107073073B
CN107073073B CN201580057704.5A CN201580057704A CN107073073B CN 107073073 B CN107073073 B CN 107073073B CN 201580057704 A CN201580057704 A CN 201580057704A CN 107073073 B CN107073073 B CN 107073073B
Authority
CN
China
Prior art keywords
pyocin
pyocins
pseudomonas aeruginosa
mice
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580057704.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073073A (zh
Inventor
丹尼尔·沃克
劳拉·麦考伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Publication of CN107073073A publication Critical patent/CN107073073A/zh
Application granted granted Critical
Publication of CN107073073B publication Critical patent/CN107073073B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580057704.5A 2014-09-23 2015-09-22 经肺施用绿脓菌素用于治疗细菌性呼吸道感染 Active CN107073073B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416788.6A GB201416788D0 (en) 2014-09-23 2014-09-23 Therapeutic applications for pyocins
GB1416788.6 2014-09-23
PCT/EP2015/071768 WO2016046218A1 (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Publications (2)

Publication Number Publication Date
CN107073073A CN107073073A (zh) 2017-08-18
CN107073073B true CN107073073B (zh) 2021-07-09

Family

ID=51869352

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580057704.5A Active CN107073073B (zh) 2014-09-23 2015-09-22 经肺施用绿脓菌素用于治疗细菌性呼吸道感染

Country Status (7)

Country Link
US (2) US11643442B2 (cg-RX-API-DMAC7.html)
EP (1) EP3200813B1 (cg-RX-API-DMAC7.html)
JP (1) JP6836506B2 (cg-RX-API-DMAC7.html)
CN (1) CN107073073B (cg-RX-API-DMAC7.html)
CA (1) CA2962117C (cg-RX-API-DMAC7.html)
GB (1) GB201416788D0 (cg-RX-API-DMAC7.html)
WO (1) WO2016046218A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857606B2 (en) 2017-12-14 2024-01-02 Bactoclear Holdings Pte. Ltd. Therapeutic bacteriocins
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
EP3957995A1 (en) * 2018-11-19 2022-02-23 Bioaster Methods and reagents for multiplex binding experiments
WO2020245376A1 (en) * 2019-06-06 2020-12-10 Nomad Bioscience Gmbh Klebicins for the control of klebsiella
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861754A (en) 1986-05-28 1989-08-29 Farkas Himsley Hannah Bacteriocins and compositions thereof in anti-viral treatment
JP3655645B2 (ja) * 1992-02-28 2005-06-02 中外製薬株式会社 経粘膜投与剤
ATE202481T1 (de) * 1996-11-15 2001-07-15 Pathogenesis Corp Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
US7700729B2 (en) * 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
JP5603070B2 (ja) * 2006-05-15 2014-10-08 アビッドバイオティクス コーポレイション 改変バクテリオシン及びその使用方法
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
US20080286236A1 (en) * 2007-05-14 2008-11-20 Avidbiotics Corporation Inhibition of yersinia pestis
CA2833176C (en) * 2011-04-12 2023-05-16 C.B. Appaiah Chimeric antibacterial polypeptides
GB201116234D0 (en) * 2011-09-20 2011-11-02 Aseptika Ltd Biomarkers for respiratory infection

Also Published As

Publication number Publication date
EP3200813A1 (en) 2017-08-09
CA2962117C (en) 2023-04-25
CA2962117A1 (en) 2016-03-31
US12162911B2 (en) 2024-12-10
JP6836506B2 (ja) 2021-03-03
US20170240602A1 (en) 2017-08-24
US11643442B2 (en) 2023-05-09
GB201416788D0 (en) 2014-11-05
CN107073073A (zh) 2017-08-18
US20230303636A1 (en) 2023-09-28
WO2016046218A1 (en) 2016-03-31
EP3200813B1 (en) 2021-04-07
JP2017529398A (ja) 2017-10-05

Similar Documents

Publication Publication Date Title
US12162911B2 (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Mühlen et al. Treatment strategies for infections with Shiga toxin-producing Escherichia coli
Lee et al. Klebsiella pneumoniae secretes outer membrane vesicles that induce the innate immune response
Totsika et al. Uropathogenic Escherichia coli mediated urinary tract infection
Waters et al. Cystic fibrosis microbiology: advances in antimicrobial therapy
JP6054371B2 (ja) 病原性疾患における細菌ｍａｍポリペプチドの調節
JP6084631B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
Dicks et al. Medical and personal care applications of bacteriocins produced by lactic acid bacteria
Yang et al. PA0833 is an OmpA C-like protein that confers protection against Pseudomonas aeruginosa infection
US20190111106A1 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
Sun et al. Pseudomonas fluorescens: iron-responsive proteins and their involvement in host infection
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
Cote-Gravel et al. Characterization of a vraG mutant in a genetically stable Staphylococcus aureus small-colony variant and preliminary assessment for use as a live-attenuated vaccine against intrammamary infections
Chen et al. Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
US20220401514A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
Yacoub et al. Effect of Nk-lysin peptides on bacterial growth, MIC, antimicrobial resistance, and viral activities
HK1241754B (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
WO2018035046A1 (en) Treating infections using idsd from proteus mirabilis
CN103690938B (zh) ATP合成酶β亚基在制备免疫保护剂、疫苗或抗细菌感染剂上的应用
Sharma et al. Antimicrobial Resistance in Acinetobacter baumannii: A Challenge to Clinical Settings
US20220227817A1 (en) Engineered globular endolysin, a highly potent antibacterial enzyme for multidrug resistant gram-negative bacteria
de Freitas e Silva et al. Capsule and PspA Cooperatively Confer Resistance of Streptococcus pneumoniae to the Human defensin HNP-1
Fortuna et al. Humoral Immune Response to Phage-Based
Lee Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC and Lee SH (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant